Hypharm competitive analysis

Explore patent oppositions filed by Hypharm against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 3, 2026
Patent NumberTitleApplicantOpposition Date
Dosage Form Containing Oxycodone And NaloxoneEURO CELTIQUEJul 26, 2023
Rapamycin Derivative For Treating Advanced Solid TumoursNOVARTISJan 6, 2023
Posaconazole Intravenous Solution Formulations Stabilized By Substituted Beta-CyclodextrinMERCK SHARP & DOHMEMay 25, 2022
Rapamycin Derivative For Treating Pancreas CancerNOVARTISFeb 14, 2020
Dosage Form Containing Oxycodone And NaloxoneEURO CELTIQUEJan 9, 2020
Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated AngiogenesisNOVARTISJul 3, 2019
A Rapamycin Derivative For Treating Lung CancerNOVARTISJun 12, 2019
Treatment Of Solid Brain Tumours With A Rapamycin DerivativeNOVARTISDec 22, 2017
Pharmaceutical Preparation Containing Oxycodone And NaloxoneEURO CELTIQUENov 7, 2017
Pharmaceutical Preparation Containing Oxycodone And NaloxoneEURO CELTIQUENov 7, 2017

Explore Hypharm's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 3, 2026
Patent NumberPublication DateTitleTotal Oppositions
Oct 28, 2020Chimeric Polypeptides And Their Use In Bacterial Decolonization1

Latest PTAB cases involving Hypharm

Discover the latest PTAB cases involving Hypharm, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Hypharm with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 3, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ETHYPHARM149 - -
EURO CELTIQUE - 73 - -
G L PHARMA18 - - -
NOVARTIS12550 - 21